Enrollment demographics and risk of developing confirmed malaria infection in REACH
| Enrollment parameter . | Confirmed malaria infections (N = 346) . | ||
|---|---|---|---|
| Malaria . | No malaria . | P value . | |
| Number of study participants | 218 | 388 | -- |
| Age (y), mean (SD) | 5.5 (2.3) | 5.4 (2.4) | .55 |
| Sex (male, %) | 117 (53.7) | 193 (49.7) | .40 |
| Pre-enrollment malaria, n (%) | 199 (91.3) | 318 (82.0) | .0019 |
| Height (cm), mean (SD) | 107.6 (14.0) | 107.7 (15.2) | .97 |
| Weight (kg), mean (SD) | 17.3 (4.3) | 17.3 (4.8) | .92 |
| Hb (g/dL), mean (SD) | 7.2 (1.2) | 7.4 (1.0) | .029 |
| MCV (fL), mean (SD) | 76.9 (9.4) | 76.2 (8.7) | .32 |
| ANC (×109/L), med (IQR) | 6.4 (5.0-8.2) | 6.1 (4.8-8.1) | .38 |
| HbF (%), mean (SD) | 10.0 (6.0) | 10.4 (6.5) | .42 |
| Spleen status | .52 | ||
| Nonpalpable, n (%) | 173 (80.8) | 312 (83.9) | |
| Palpable (1-4 cm), n (%) | 18 (8.4) | 32 (8.6) | |
| Palpable (≥5 cm), n (%) | 19 (8.9) | 25 (6.7) | |
| Splenectomy, n (%) | 4 (1.9) | 3 (0.8) | |
| α-thalassemia genotypes | .15 | ||
| 2 gene deletion (−α3.7/−α3.7) | 21 (9.6) | 43 (11.1) | |
| 1 gene deletion (−α3.7/αα) | 95 (43.6) | 195 (50.3) | |
| None (αα/αα) | 102 (46.8) | 150 (38.7) | |
| G6PD genotypes | .30 | ||
| Male unaffected | 99 (84.6) | 150 (77.7) | |
| Male hemizygous | 18 (15.4) | 43 (22.3) | |
| Female unaffected | 65 (64.4) | 124 (63.6) | |
| Female heterozygous | 32 (31.7) | 68 (34.9) | |
| Female homozygous | 4 (4.0) | 3 (1.5) | |
| Enrollment parameter . | Confirmed malaria infections (N = 346) . | ||
|---|---|---|---|
| Malaria . | No malaria . | P value . | |
| Number of study participants | 218 | 388 | -- |
| Age (y), mean (SD) | 5.5 (2.3) | 5.4 (2.4) | .55 |
| Sex (male, %) | 117 (53.7) | 193 (49.7) | .40 |
| Pre-enrollment malaria, n (%) | 199 (91.3) | 318 (82.0) | .0019 |
| Height (cm), mean (SD) | 107.6 (14.0) | 107.7 (15.2) | .97 |
| Weight (kg), mean (SD) | 17.3 (4.3) | 17.3 (4.8) | .92 |
| Hb (g/dL), mean (SD) | 7.2 (1.2) | 7.4 (1.0) | .029 |
| MCV (fL), mean (SD) | 76.9 (9.4) | 76.2 (8.7) | .32 |
| ANC (×109/L), med (IQR) | 6.4 (5.0-8.2) | 6.1 (4.8-8.1) | .38 |
| HbF (%), mean (SD) | 10.0 (6.0) | 10.4 (6.5) | .42 |
| Spleen status | .52 | ||
| Nonpalpable, n (%) | 173 (80.8) | 312 (83.9) | |
| Palpable (1-4 cm), n (%) | 18 (8.4) | 32 (8.6) | |
| Palpable (≥5 cm), n (%) | 19 (8.9) | 25 (6.7) | |
| Splenectomy, n (%) | 4 (1.9) | 3 (0.8) | |
| α-thalassemia genotypes | .15 | ||
| 2 gene deletion (−α3.7/−α3.7) | 21 (9.6) | 43 (11.1) | |
| 1 gene deletion (−α3.7/αα) | 95 (43.6) | 195 (50.3) | |
| None (αα/αα) | 102 (46.8) | 150 (38.7) | |
| G6PD genotypes | .30 | ||
| Male unaffected | 99 (84.6) | 150 (77.7) | |
| Male hemizygous | 18 (15.4) | 43 (22.3) | |
| Female unaffected | 65 (64.4) | 124 (63.6) | |
| Female heterozygous | 32 (31.7) | 68 (34.9) | |
| Female homozygous | 4 (4.0) | 3 (1.5) | |
SD, standard deviation; IQR, 25% to 75% interquartile range.